Multiple myeloma remains challenging to treat. New therapeutic advances have improved outcomes, but selecting the right treatment for a patient can be complex because the disease can vary drastically from person to person. ...
Feb 9, 2024
0
0
Cedars-Sinai Cancer investigators have discovered a protein expressed on multiple myeloma cancer cells that drives disease growth and development. The new study found that blocking part of the protein's unique signaling pathway ...
Feb 7, 2024
0
336
Proteasomes are protein-degrading complexes that are important for cancer cell survival. Proteasome inhibitors are commonly used to treat diseases such as multiple myeloma and mantle cell lymphoma. Proteasomes have three ...
Dec 14, 2023
0
15
Multiple myeloma (MM) is one of the most formidable and deadly cancers known to man, with only 50% of patients surviving for more than five years after diagnosis.
Nov 28, 2023
0
5
Multiple myeloma is still an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment. Immunotherapy is an attractive strategy to ...
Nov 17, 2023
0
1
All cancer cells—even those within the same tumor—differ from each other and change over the course of a cancer disease. Scientists at Heidelberg University Hospital, the Medical Faculty in Heidelberg and the German Cancer ...
Nov 10, 2023
0
23
Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according ...
Oct 19, 2023
0
1
Researchers from Uppsala University have revealed one of the mechanisms behind the growth of cancer cells in the blood cancer multiple myeloma. The study shows that the protein EZH2 interacts with a specific RNA molecule ...
Sep 29, 2023
0
2
Combining five existing drugs can keep a highly aggressive type of bone marrow cancer at bay for longer, an innovative trial has shown.
Jun 23, 2023
0
20
Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. Patients treated with higher doses of ...
Apr 17, 2023
0
2
